Clinical trials: Headache Migraine Chronic
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Chronic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
- Trial name
- REBUILD-2 (NCT04616326)
- Testing
- Galcanezumab
- Where
- 88 sites in United States, Denmark and 9 more
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine Headache
Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.
Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache greater than 15 days per month.
- Trial name
- ONSTIM (NCT00200109)
- Testing
- Occipital Nerve Stimulation
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Migraine Disorders
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
- Trial name
- NCT01516892
- Testing
- onabotulinumtoxinA
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 716 people
- Sponsor
- Allergan
Migraine, Migraine Disorders
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
- Conditions
- Migraine, Migraine Disorders, Migraine Headache
- Trial name
- APOLLON (NCT04084314)
- Testing
- Erenumab
- Where
- 75 sites in Germany
- Volunteers
- 701 people
- Sponsor
- Novartis Pharmaceuticals
Migraine, Chronic Migraine
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again.
- Trial name
- NCT06428838
- Testing
- Eptinezumab, Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Dr George Medvedev
Migraine
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine
The purpose of this study is to illustrate the safety and effectiveness of the StimRelieve Halo Nerve Stimulator System in the treatment of chronic migraine.
- Trial name
- NCT02725554
- Testing
- StimRelieve Halo System
- Sponsor
- Curonix LLC
Migraine Disorders
A Multicenter Assessment of ALD403 in Chronic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- NCT02275117
- Testing
- ALD403
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 665 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
- Trial name
- REJOIN (NCT05164172)
- Testing
- Eptinezumab
- Where
- 64 sites in United States, Argentina and 9 more
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Preventive Treatment of Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every…
- Trial name
- NCT07729462
- Testing
- Rimegepant
- Where
- 21 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Pfizer